Additionally, there is also evidence of alternative pathway activation in primary membranous nephropathy as supported by genetic evidence for the deposition of PLA2R antibody, C3, and C5b-9 in patients with MBL deficiency (80) and via production of antibodies targeting CFH (81). This evidence concerns the gene MBL2 and membranous glomerulonephritis.